Medexus Pharmaceuticals Inc.

TSX:MDP Voorraadrapport

Marktkapitalisatie: CA$59.9m

Medexus Pharmaceuticals Inkomsten in het verleden

Verleden criteriumcontroles 1/6

Medexus Pharmaceuticals has been growing earnings at an average annual rate of 30.8%, while the Pharmaceuticals industry saw earnings growing at 46% annually. Revenues have been growing at an average rate of 18.7% per year. Medexus Pharmaceuticals's return on equity is 3.4%, and it has net margins of 1%.

Belangrijke informatie

30.8%

Groei van de winst

33.7%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie23.1%
Inkomstengroei18.7%
Rendement op eigen vermogen3.4%
Nettomarge1.0%
Volgende winstupdate07 Nov 2024

Recente prestatie-updates uit het verleden

There May Be Reason For Hope In Medexus Pharmaceuticals' (TSE:MDP) Disappointing Earnings

Aug 19
There May Be Reason For Hope In Medexus Pharmaceuticals' (TSE:MDP) Disappointing Earnings

Recent updates

There May Be Reason For Hope In Medexus Pharmaceuticals' (TSE:MDP) Disappointing Earnings

Aug 19
There May Be Reason For Hope In Medexus Pharmaceuticals' (TSE:MDP) Disappointing Earnings

Medexus Pharmaceuticals Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Aug 10
Medexus Pharmaceuticals Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Medexus Pharmaceuticals Inc. (TSE:MDP) Shares Fly 29% But Investors Aren't Buying For Growth

Jul 31
Medexus Pharmaceuticals Inc. (TSE:MDP) Shares Fly 29% But Investors Aren't Buying For Growth

The Market Doesn't Like What It Sees From Medexus Pharmaceuticals Inc.'s (TSE:MDP) Revenues Yet

Jun 15
The Market Doesn't Like What It Sees From Medexus Pharmaceuticals Inc.'s (TSE:MDP) Revenues Yet

Here's Why Medexus Pharmaceuticals (TSE:MDP) Has A Meaningful Debt Burden

Apr 25
Here's Why Medexus Pharmaceuticals (TSE:MDP) Has A Meaningful Debt Burden

Revenues Working Against Medexus Pharmaceuticals Inc.'s (TSE:MDP) Share Price Following 26% Dive

Mar 03
Revenues Working Against Medexus Pharmaceuticals Inc.'s (TSE:MDP) Share Price Following 26% Dive

Medexus Pharmaceuticals Inc.'s (TSE:MDP) Shares Leap 89% Yet They're Still Not Telling The Full Story

Jan 06
Medexus Pharmaceuticals Inc.'s (TSE:MDP) Shares Leap 89% Yet They're Still Not Telling The Full Story

Here's Why Medexus Pharmaceuticals (TSE:MDP) Has Caught The Eye Of Investors

Oct 11
Here's Why Medexus Pharmaceuticals (TSE:MDP) Has Caught The Eye Of Investors

Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?

Sep 11
Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?

Medexus Pharmaceuticals (TSE:MDP) Use Of Debt Could Be Considered Risky

Jan 19
Medexus Pharmaceuticals (TSE:MDP) Use Of Debt Could Be Considered Risky

Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?

Sep 22
Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?

Is Medexus Pharmaceuticals (TSE:MDP) Weighed On By Its Debt Load?

Dec 16
Is Medexus Pharmaceuticals (TSE:MDP) Weighed On By Its Debt Load?

Medexus Pharmaceuticals Inc. (TSE:MDP) Analysts Just Cut Their EPS Forecasts Substantially

Aug 21
Medexus Pharmaceuticals Inc. (TSE:MDP) Analysts Just Cut Their EPS Forecasts Substantially

Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?

Aug 04
Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?

Opbrengsten en kosten

Hoe Medexus Pharmaceuticals geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

TSX:MDP Opbrengsten, kosten en inkomsten (USD Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Jun 241091431
31 Mar 241130452
31 Dec 231166462
30 Sep 231195473
30 Jun 231173483
31 Mar 231081483
31 Dec 22100-11473
30 Sep 2292-11463
30 Jun 22822444
31 Mar 2277-3446
31 Dec 2174-8447
30 Sep 2177-20437
30 Jun 2177-31406
31 Mar 2180-28365
31 Dec 2079-19333
30 Sep 2069-9312
30 Jun 2064-7312
31 Mar 2056-5311
31 Dec 1947-4311
30 Sep 1945-3290
30 Jun 1936-6220
31 Mar 1925-5160
31 Dec 1817-5100
30 Sep 189-560
30 Jun 188-260
31 Mar 188-360
31 Dec 178-360
30 Sep 177-360
30 Jun 176-360
31 Mar 175-150
31 Dec 164150
30 Sep 163150
30 Jun 163150
31 Mar 163-250
31 Dec 153-450
30 Sep 152-450
30 Jun 152-560
31 Mar 152-460
31 Dec 143-460
30 Sep 143-450
30 Jun 144-350
31 Mar 143-350
31 Dec 134-240

Kwaliteitswinsten: MDP has a large one-off loss of $2.3M impacting its last 12 months of financial results to 30th June, 2024.

Groeiende winstmarge: MDP's current net profit margins (1%) are lower than last year (2.8%).


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: MDP has become profitable over the past 5 years, growing earnings by 30.8% per year.

Versnelling van de groei: MDP's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Winst versus industrie: MDP had negative earnings growth (-66.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-40.8%).


Rendement op eigen vermogen

Hoge ROE: MDP's Return on Equity (3.4%) is considered low.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden